Similar articles for PMID: 23362949

Year	Number of Results
1983	1
1989	1
1991	1
1992	1
1993	1
1994	1
1996	2
1997	4
1998	2
1999	3
2000	5
2001	3
2002	3
2003	2
2004	4
2005	4
2006	2
2007	3
2008	3
2009	1
2010	2
2011	2
2012	2
2013	3
2014	1
2015	1
2016	2
2017	2
2022	1
2023	1
2024	0

1

Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice.

Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Pommergaard HC, et al. Cancer Invest. 2013 Feb;31(2):92-6. doi: 10.3109/07357907.2012.762782. Cancer Invest. 2013. PMID: 23362949

2

Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.

Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Pommergaard HC, et al. Anticancer Res. 2013 Aug;33(8):3033-9. Anticancer Res. 2013. PMID: 23898057

3

Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice.

Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Pommergaard HC, et al. J Chemother. 2014 Apr;26(2):105-10. doi: 10.1179/1973947813Y.0000000117. Epub 2013 Dec 6. J Chemother. 2014. PMID: 24090798

4

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS. Jeter JM, et al. Cancer Prev Res (Phila). 2016 Feb;9(2):128-34. doi: 10.1158/1940-6207.CAPR-15-0232. Epub 2015 Dec 28. Cancer Prev Res (Phila). 2016. PMID: 26712942 Free PMC article. Clinical Trial.

5

Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice.

Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Lerche CM, et al. Exp Dermatol. 2010 Nov;19(11):973-9. doi: 10.1111/j.1600-0625.2009.01034.x. Exp Dermatol. 2010. PMID: 20113348

6

Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer.

Hess LM, Saboda K, Malone DC, Salasche S, Warneke J, Alberts DS. Hess LM, et al. Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2579-83. doi: 10.1158/1055-9965.EPI-05-0104. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16284381 Clinical Trial.

7

Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.

Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS. Einspahr JG, et al. Clin Cancer Res. 2002 Jan;8(1):149-55. Clin Cancer Res. 2002. PMID: 11801552 Clinical Trial.

8

Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice.

Rebel H, van Steeg H, Beems RB, Schouten R, de Gruijl FR, Terleth C. Rebel H, et al. Cancer Res. 2002 Mar 1;62(5):1338-42. Cancer Res. 2002. PMID: 11888902

9

Chemoprevention of nonmelanoma skin cancer.

Wright TI, Spencer JM, Flowers FP. Wright TI, et al. J Am Acad Dermatol. 2006 Jun;54(6):933-46; quiz 947-50. doi: 10.1016/j.jaad.2005.08.062. J Am Acad Dermatol. 2006. PMID: 16713450 Review.

10

Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.

Arbeit JM, Riley RR, Huey B, Porter C, Kelloff G, Lubet R, Ward JM, Pinkel D. Arbeit JM, et al. Cancer Res. 1999 Aug 1;59(15):3610-20. Cancer Res. 1999. PMID: 10446971

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

59 results

Results by year